Bioimpacts最新文献

{"title":"Designing of multi-epitope vaccine against Varicella zoster virus (VZV) using immunoinformatics and structural analysis: In silico study.","authors":"Mohamed J Saadh, Mareb Hamed Ahmed, Rafid Jihad Albadr, Gaurav Sanghvi, R Roopashree, Aditya Kashyap, A Sabarivani, Zafar Aminov, Waam Mohammed Taher, Mariem Alwan, Mahmod Jasem Jawad, Ali M Ali Al-Nuaimi","doi":"10.34172/bi.30994","DOIUrl":"10.34172/bi.30994","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>The Varicella-zoster virus (VZV) causes varicella (chickenpox) and herpes zoster (shingles), posing significant global health challenges. Despite existing vaccines, gaps in coverage and efficacy persist, necessitating novel vaccine designs. This study aimed to develop a multi-epitope vaccine targeting VZV using immunoinformatics and structural bioinformatics approaches.</p><p><strong>Methods: </strong>MHC-I and MHC-II binding epitopes from VZV proteins (glycoprotein E, glycoprotein B, tegument protein IE63) were predicted using IEDB tools, prioritizing conserved epitopes with high binding affinity. A chimeric construct was engineered with 18 epitopes, adjuvants (β-defensin 3), and cell-penetrating peptides (HIV TAT), linked with GPGPG/AAY spacers. Antigenicity (VaxiJen), allergenicity (AlgPred), physicochemical properties (ProtParam), and solubility (SOLpro) were assessed. Tertiary structure modeling (GalaxyWEB) and refinement (GalaxyRefine) were performed. Docking (PatchDock) and dynamics simulations (GROMACS, 100 ns) evaluated TLR2-vaccine binding stability. Immune response was simulated (C-ImmSim), and codon optimization (JCAT) ensured <i>E. coli</i> expression compatibility.</p><p><strong>Results: </strong>Non-allergenic, antigenic (VaxiJen score: 0.52), stable (instability index: 30.20), and soluble (GRAVY: -0.548). Molecular weight: 34 kDa; pI: 9.65. RMSD (3.8 nm) and RMSF analyses confirmed complex stability. Free energy landscape revealed low-energy binding states (0.3-1.8 kcal/mol). Simulated results showed robust IgG/IgM production, Th1 cytokines (IFN-γ, IL-2), and memory cell activation. Epitopes covered 100% of populations in Europe/North America and > 77% in Africa/South Asia.</p><p><strong>Conclusion: </strong>The multi-epitope vaccine demonstrated strong immunogenicity, structural stability, and broad population coverage. Computational validation supports its potential as a candidate for preventing VZV infections, pending experimental verification in the future.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30994"},"PeriodicalIF":2.2,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A subspace learning aided matrix factorization for drug repurposing.","authors":"Amir Mahdi Zhalefar, Zahra Narimani","doi":"10.34172/bi.30443","DOIUrl":"10.34172/bi.30443","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Design and development of new drugs needs a huge amount of investment of time and money. The advent of machine learning and computational biology has led to sophisticated techniques for drug repositioning, i.e., recommending available drugs for new diseases or, more specifically, protein targets. However, there remains a critical need for improved synergy between these techniques to enhance their predictive accuracy and practical application in clinical settings.</p><p><strong>Methods: </strong>This study presents a novel approach that integrates two methodologies: SLSDR, a sparse and low-redundant subspace learning-based dual-graph regularized robust feature selection technique, and the iDrug method for drug repurposing which integrates different domains. SLSDR is a subspace learning algorithm based on matrix factorization, and iDrug is a matrix factorization-based drug repositioning method that integrates data from two different domains (drug-disease and drug-target domains). By leveraging SLSDR's ability to extract essential features from drug-disease and drug-target spaces, we enhance the iDrug objective function. Our approach includes constructing a drug-drug similarity matrix using a feature space derived from SLSDR, and target-target and disease-disease similarity matrices. This ensures a comprehensive representation of drug-disease and drug-target associations. We introduce a novel objective function that captures the nuanced interactions between drugs and diseases, considering the complex interrelationships among features within all the datasets.</p><p><strong>Results: </strong>By integrating these components, our strategy offers a holistic solution for drug repositioning, optimizing the prediction process. In terms of prediction accuracy, AUC, AUPR and computing efficiency, the results indicate notable gains over the state of the art drug repurposing methods. Fig. 1, represents the comparison of the performance of the proposed method with existing approaches across various metrics.</p><p><strong>Conclusion: </strong>The proposed matrix factorization based method for drug repurposing, benefits from integrating knowledge from two domains, drug-disease and drug-target domains, and also is capable of preserve the geometry of the data in both feature space, and s ample space. Comparing to existing state of the art methods, this shows accuracy improvement in drug repurposing.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30443"},"PeriodicalIF":2.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"microRNAs shuttled by mesenchymal stromal cell-derived exosomes in coronary artery disease: A systematic review of preclinical studies.","authors":"Soroush Mostafavi, Amin Arasteh, Seyedeh Mina Mostafavi Montazeri, Seyyedeh Mina Hejazian, Farahnoosh Farnood, Sima Abediazar, Abolfazl Barzegari, Sepideh Zununi Vahed","doi":"10.34172/bi.30989","DOIUrl":"10.34172/bi.30989","url":null,"abstract":"<p><strong>Introduction: </strong>Coronary artery disease (CAD) is a life-threatening cardiac condition with high morbidity and mortality worldwide. This systematic review article highlighted the therapeutic roles of mesenchymal stromal cells (MSCs)-derived exosomal microRNAs (exo-miRs) in preclinical models of CAD.</p><p><strong>Methods: </strong>A comprehensive search was conducted on PubMed, Web of Science, Scopus, and Google Scholar to identify relevant publications until 04 Apr 2025. The literature review focuses on the origin of MSCs, the technique employed for exosome extraction and identification, the route and frequency of exosomal administration, the mechanisms through which exo-miRs regulate paracrine activity, and their impact on cardiac outcome.</p><p><strong>Results: </strong>After meticulous evaluation, fifty-six studies were deemed eligible for inclusion in this systematic review. Bone marrow-derived MSCs were the most commonly utilized cell type in the preclinical studies. The majority of studies employed the ultracentrifugation method for exosome isolation from MSCs. The administration of exosomes was primarily achieved through a single intramyocardial injection, utilizing a wide range of exosome concentrations (ranging from 0.02-400 μg/μL).</p><p><strong>Conclusion: </strong>The included studies predominantly have reported the anti-inflammatory, anti-apoptotic, angiogenic, antifibrotic, and reparative effects of MSC-exo-miRs, especially under hypoxic conditions. These findings support the capacity of MSC-exo-miRs to regulate the immune system and facilitate cardiac recovery following an injury.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30989"},"PeriodicalIF":2.2,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing cancer therapy: Monoclonal antibodies in radiosensitization.","authors":"Abolfazl Bemidinezhad, Yasaman Abolhassani, Mojgan Noroozi-Karimabad, Arman Abroumand Gholami, Abbas Alalikhan, Ramin Roshani, Mohammad Parsa-Kondelaji, Fatemeh Gheybi","doi":"10.34172/bi.30996","DOIUrl":"10.34172/bi.30996","url":null,"abstract":"<p><p>Cancer treatment has advanced significantly, yet traditional modalities such as radiotherapy still encounter challenges, including damage to healthy tissues and limited tumor specificity. Monoclonal antibodies (mAbs) have emerged as powerful tools in oncology, offering particular therapeutic options with reduced toxicity. Their capacity to enhance the efficacy of radiotherapy through radiosensitization presents a promising strategy for improving cancer outcomes. This review synthesizes findings from the past decade, providing an in-depth analysis of the diverse roles of mAbs in radiosensitization. Key mechanisms are discussed, including targeting molecular pathways, modulation of immune responses, and integration with novel platforms such as nanoparticles and antibody-drug conjugates (ADCs). The review also highlights the successes of preclinical and clinical studies while addressing ongoing challenges like delivery inefficiencies, tumor resistance, and antigen heterogeneity. Additionally, emerging alternatives including aptamers, nanobodies, and engineered proteins are explored as potential solutions to these barriers. Advancements in mAb-based delivery systems and combination therapies remain crucial for achieving more personalized and effective cancer treatments.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30996"},"PeriodicalIF":2.2,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent innovations in nanomedicine and nano-based techniques for the treatment of breast cancer.","authors":"Meena Bhandari, Seema Raj, Md Sabir Alam","doi":"10.34172/bi.30804","DOIUrl":"10.34172/bi.30804","url":null,"abstract":"<p><p>Breast cancer (BC) is a persistent global health challenge, necessitating innovative therapeutic strategies. Recently, nanotechnology has appeared as a transformative methodology to treat BC, suggesting precise targeting, controlled drug delivery, and improved imaging capabilities. This review offers a current overview of the latest innovations around nanotechnology for BC therapy in the field of new nanomedicines and nano-based drug delivery methods by carefully examining the utilization of nanoparticles to enhance the effectiveness of both new and old medications and to enable targeted evaluation using disease markers. Key topics include early detection, targeted drug delivery, multimodal imaging, and combination therapies. The paper underscores the probability of using nanotechnology to reshape BC management landscape and outlines potential future directions.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30804"},"PeriodicalIF":2.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigate the co-culture effects of BM-mesenchymal stem cells on the promotion of apoptotic pathways of CD34⁺leukemic stem cells.","authors":"Mei Ding, Chuanhua Jia","doi":"10.34172/bi.31302","DOIUrl":"10.34172/bi.31302","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>The potential clinical application of mesenchymal stem cells (MSCs) in cell-based treatment makes them particularly interesting. The use of MSC-engaged therapies in cancer treatment is becoming more and more promising. Although the specifics of their activity have not yet been conclusively established, a variety of growth factors released by these cells are known to provide such multifunctional qualities.</p><p><strong>Methods: </strong>Through the measurement of cytokine levels, Annexin-V, and possible signaling pathways linked to apoptosis, we have assessed the impact of MSCs on CD34⁺leukemic stem cells (LSCs) enriched from the KG1-a cell line. Additionally, culture medium was taken from the experimental and control groups for the IL-2 and IL-4 measurement following a 7-day co-culture.</p><p><strong>Results: </strong>Co-culture conditions were observed to promote early and late apoptosis, although this increase just was statistically significant in late apoptosis. The co-cultured conditioned media clearly showed a large amount of IL-2, but there was an insignificant rise in IL-4. Also, MSCs significantly increased the protein expression of P16, P21, and p-P38 and significantly decreased C-Myc, and TERC.</p><p><strong>Conclusion: </strong>It can be concluded that the mentioned effects of IL-2 cytokine released from MSCs on CD34⁺LSCs maybe were applied by the components of P16, P21, and p-P38, C-Myc signaling pathways.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"31302"},"PeriodicalIF":2.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic Treg-derived artificial vesicles: A promising therapeutic modality for multiple sclerosis.","authors":"Irina Alekseevna Ganeeva, Elvina Maratovna Gilyazova, Arthur Ajdarovich Khannanov, Mariia Eugenievna Nektorova, Alexey Michailovich Rogov, Timur Ildarovich Khaibullin, Ekaterina Anatolievna Zmievskaya, Emil Rafaelevich Bulatov","doi":"10.34172/bi.30880","DOIUrl":"10.34172/bi.30880","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). CD4⁺ CD25^+hi Tregs, which normally suppress immune responses, exhibit impaired function in MS. Treg-derived extracellular vesicles (EVs) carry immunoregulatory proteins and miRNAs that modulate T-cell activity. However, EVs from MS patients show reduced suppressive capacity, suggesting their dysfunction contributes to MS pathogenesis. This highlights EVs' potential role in MS development and therapy.</p><p><strong>Methods: </strong>Tregs were differentiated from naïve T cells isolated from peripheral blood mononuclear cells (PBMCs) of healthy donor, then transduced with B2M-shRNA lentivirus to generate HLA class I-knockdown Tregs. Extracellular vesicles-including natural vesicles, cytochalasin B-induced artificial vesicles, and ultrasound-induced artificial vesicles-were isolated from Tregs and characterized by scanning electron microscopy (SEM), nanoparticle tracking analysis (NTA), flow cytometry, and Western blot. Their effects on healthy donor and MS patient PBMCs were evaluated via flow cytometry and ELISA (IL-6, IL-10, IFN-γ).</p><p><strong>Results: </strong>Ultrasonication yielded a higher number оf vesicles enriched with key immunosuppressive proteins, including PD-1 and Tim-3, compared to cytochalasin B. Functional assays demonstrated the ability оf ultrasonication-induced AVs to suppress inflammatory markers, such as IFNγ, and modulate the cytokine profile in both healthy and MS-derived PBMCs.</p><p><strong>Conclusion: </strong>Developing effective MS therapies remains challenging. While cellular therapies face limitations like Treg dysfunction and CNS delivery issues, allogeneic EVs offer a promising alternative due to their scalability, low immunogenicity, and blood-brain barrier penetration. We developed Treg-derived artificial vesicles (TrAVs) that maintain immunosuppressive properties and modulate PBMC responses, suggesting therapeutic potential for MS. Further research is needed to optimize production and validate efficacy in disease models.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30880"},"PeriodicalIF":2.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA-372-3p impairs fatty acid metabolism in hepatocellular carcinoma cells by targeting <i>CPT1A</i> and <i>ACSL4</i>.","authors":"Chinnatam Phetkong, Thammachanok Boonto, Pannathon Thamjamrassri, Chaiyaboot Ariyachet, Pisit Tangkijvanich","doi":"10.34172/bi.31075","DOIUrl":"10.34172/bi.31075","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) remains a major cause of cancer mortality, and effective therapeutic options are limited. MicroRNA‑372‑3p (miR‑372‑3p) has been implicated in HCC, yet its exact role is unclear.</p><p><strong>Methods: </strong>We established miR‑372‑3p‑overexpressing HCC cell lines (HepG2, SNU‑449, JHH‑4) via lentiviral transduction. Malignant phenotypes were assessed with MTT, transwell migration/invasion, and colony‑formation assays. Transcriptomic changes were analyzed by RNA‑sequencing followed by Gene Set Enrichment Analysis. Lipid metabolism was examined using BODIPY/Oil Red O staining, triglyceride quantification, FAOBlue assays, and organelle colocalization imaging. Candidate targets of miR‑372‑3p were computationally predicted and validated by dual‑luciferase reporter assays.</p><p><strong>Results: </strong>miR‑372‑3p overexpression significantly reduced cell proliferation by more than 50%, migration by over 30%, invasion by over 30%, and colony formation by more than 50%, supporting its tumor-suppressive role. Transcriptomic analysis identified 1,759 downregulated genes, significantly enriched in pathways associated with fatty acid oxidation (FAO). miR‑372‑3p‑overexpressing cells exhibited increased lipid droplet accumulation, with triglyceride levels elevated by more than 50% and an approximate 50% reduction in FAO activity, indicating defective use under glucose-deprived conditions. High-resolution organelle imaging further revealed diminished physical contacts between lipid droplets and mitochondria, as well as a similar disruption in lipid droplet-lysosome interactions. Dual-luciferase reporter assays confirmed <i>CPT1A</i> and <i>ACSL4</i> as direct targets of miR‑372‑3p.</p><p><strong>Conclusion: </strong>miR‑372‑3p functions as a tumor suppressor in HCC by directly downregulating <i>CPT1A</i> and <i>ACSL4</i>, thereby inhibiting FAO and disrupting lipid metabolism. Targeting this miRNA and FAO axis may offer a novel therapeutic strategy for HCC.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"31075"},"PeriodicalIF":2.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development, in vitro, and in vivo assessments of PCL-gelatin-βTCP fibrous scaffolds for cardiac regeneration.","authors":"Mahnaz Fathi, Nafiseh Baheiraei, Nahid Moradi, Majid Salehi, Sepehr Zamani, Mehdi Razavi, Hossein Eyni","doi":"10.34172/bi.31096","DOIUrl":"10.34172/bi.31096","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Cardiovascular disease is a leading cause of death worldwide. Tissue engineering offers a promising solution for promoting tissue regeneration at the infarcted site. In this study, beta-tricalcium phosphate (βTCP) was incorporated into poly(ε-caprolactone) (PCL) and gelatin (Gel) fibers for cardiac patch applications.</p><p><strong>Methods: </strong>Electrospun scaffolds were prepared via electrospinning a 1:1 (w/w) mixture of PCL and Gel, embedding varying concentrations of βTCP at 0.25, 0.5, 1, and 3 wt.%. The scaffolds were analyzed through scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), tensile strength testing, hemolysis assays, toxicity testing, and quantitative reverse transcription polymerase chain reaction (qRT-PCR) for marker gene expression. Furthermore, subcutaneous scaffold implantation was performed to assess in vivo angiogenesis in NMRI mice. Tissue samples were examined using hematoxylin and eosin (H&E) staining and immunohistochemistry.</p><p><strong>Results: </strong>According to the results, βTCP was uniformly distributed throughout the fiber scaffold, exhibiting a smooth, unbranched morphology with fiber diameters of approximately 75 μm. Specifically, the mean diameters for PCL-Gel and PCL-Gel-βTCP at 3 wt.% were 45.01 ± 2.82 μm and 100.91 ± 11.69 μm, respectively. Mechanical property assessments revealed that the elastic modulus of the scaffolds was suitable for usage as a tissue-engineered cardiac patch. Scaffolds containing βTCP exhibited favorable blood compatibility and indicated no cytotoxicity at the tested concentrations. Furthermore, the expression levels of cardiac marker genes (Actn4, Connexin43, and TrpT2) were elevated in the treatment groups in conjunction with the escalation of βTCP dosage. Fiber composites with 1% βTCP were selected as the optimal scaffold for <i>in vivo</i> examination. This scaffold demonstrated a significantly enhanced cell migration rate, with a growth in capillary formation observed in the immunohistochemistry analysis.</p><p><strong>Conclusion: </strong>The fibrous PCL-Gel-βTCP-1% scaffold showed optimal cell proliferation, blood compatibility and vascularization. These properties highlight its promise for cardiac tissue engineering.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"31096"},"PeriodicalIF":2.2,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers for colorectal cancer detection: An insight into colorectal cancer and FDA-approved biomarkers.","authors":"Mohammad Yasin Zamanian, Darmadi Darmadi, Razieh Darabi, Raed Fanoukh Aboqader Al-Aouadi, Mehraveh Sadeghi Ivraghi, Esra Küpeli Akkol","doi":"10.34172/bi.31211","DOIUrl":"10.34172/bi.31211","url":null,"abstract":"<p><p>Colorectal cancer (CRC) constitutes a significant global health challenge, accounting for a considerable proportion of cancer cases and associated mortality. Projections indicate a potential increase in new cases by 2040, attributed to demographic factors such as aging and population growth. Although advancements in the understanding of CRC pathophysiology have broadened treatment options, challenges such as drug resistance and adverse effects persist, highlighting the necessity for enhanced diagnostic methodologies. Timely detection markedly improves survival rates; however, colonoscopy, regarded as the gold standard for CRC screening, is constrained by its invasiveness and reliance on practitioner expertise. Consequently, the development of novel diagnostic approaches is imperative. Cancer biomarkers, which serve as indicators of cancer progression, show significant promise for improving diagnosis, prognosis, and treatment strategies. This study investigates molecular and cellular biomarkers, including proteins, DNA mutations, methylation markers, and microRNAs, that are pivotal in precision medicine and the monitoring of CRC progression. Additionally, emerging biomarkers such as circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs) present opportunities for early detection. Current Food and Drug Administration (FDA)-approved CRC biomarkers reflect a shift towards personalized medicine, enhancing patient compliance and clinical outcomes. Nevertheless, further research is essential for the discovery of novel biomarkers and for deepening the understanding of CRC etiology, thereby advancing personalized care. Addressing standardization challenges will be crucial for ensuring global patient access to biomarker-based strategies.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"31211"},"PeriodicalIF":2.2,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}